Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

September 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

European Academy of Dermatology and Venereology (EADV) 2024

Amy Wang, Bin Yang, Anand Ramanathan, Alamgir Hossain, Karen Yuan, Huijun Dong, Bruce Follows, Sean Zhu, Chris Browne, Andreas Harsch, Ralf Schmidt, Mike Weis, Rupa Sawant, Bradley Enerson, Jing Yuan, Richard Miller, Matt Weiss, Anthony Slavin, Nello Mainolfi

Kymera Therapeutics EADV STAT6 Poster Image September 2024
Area of Focus
Immunology
Programs
STAT6 (KT-621)
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link